The deal announced on Thursday, covering Novo's Wegovy and Lilly's Zepbound, will reduce monthly prices for U.S. government ...
Eli Lilly collaborates with the Trump administration to improve access to GLP-1 receptor agonists for millions of Americans, including those on government programs. The agreement allows Medicare ...
The White House today announced landmark drug pricing agreements with Eli Lilly and Company and Novo Nordisk to lower the ...
Novo Nordisk A/S & Eli Lilly and Company cut prices for top diabetes drugs, boosting accessibility and potential revenue.
Zacks Investment Research on MSN
LLY's GLP-1 Duo Boosts Sales Amid Rising Demand for Obesity Drugs
Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Despite ...
India Today on MSN
Weekly weight-loss shot Mounjaro is now India's top-selling drug
With obesity rates soaring and demand for effective treatments surging, Mounjaro's meteoric rise could redefine India's ...
The White House November 6, 2025 I. A Historic Advance in Most-Favored-Nation Pricing Today, President Donald J. Trump has ...
A deal with drugmakers also means that Medicare would cover obesity drugs for the first time. But certain limitations persist ...
"The White House Medical Unit quickly jumped into action, and the gentleman is okay," White House press secretary Karoline Leavitt said.
A representative for pharmaceutical company Eli Lilly says that the man is now "receiving the best medical care." ...
Press Release President Donald J. Trump announced agreements with Eli Lilly and Novo Nordisk to reduce prices of available ...
The deal offers popular weight loss drugs to be sold for as low as $149 on President Donald Trump's direct-to-consumer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback